ADVERTISEMENT
ADVERTISEMENT

Andrew C. von Eschenbach

Just one month after Andrew von Eschenbach was sworn in as National Cancer Institute director, he was called to a US Senate hearing as the government's lead witness that day. The topic was one that he had grappled with before during his tenure at the American Cancer Society—and one that his predecessor and other physicians had not endured well: the pitched debate over the effectiveness of mammography screening for women in their 40s. The hearing was triggered by a systematic review1 that c

Laura Newman
Just one month after Andrew von Eschenbach was sworn in as National Cancer Institute director, he was called to a US Senate hearing as the government's lead witness that day. The topic was one that he had grappled with before during his tenure at the American Cancer Society—and one that his predecessor and other physicians had not endured well: the pitched debate over the effectiveness of mammography screening for women in their 40s. The hearing was triggered by a systematic review1 that concluded that mammography screening offered no benefit and could confer harm in the form of excess tumorectomies and excess mastectomies. Government officials in the United States were up in arms over the message.

Von Eschenbach put forward a certain, affirmative stance at the hearing. He quelled any concerns of politicians who in unison agreed that airing any uncertainties surrounding mammography's benefits would confuse women and be bad...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
ADVERTISEMENT